Table 6.

Characteristics of the new oral anticoagulants

	Rivaroxaban [48]	Apixiban [49]	Dabigatran [50]
Coagulation target	Factor Xa	Factor Xa	Thrombin
Bioavailability (%)	80–100	50	6.5
Protein binding (%)	92–95	87	35
Half-life (h)	5–13	12	12–14 (27 in CKD4/5)
Renal clearance (%)	33	27	85
Approved for CrCl <30 mL/min	Yes. Reduce dose in CrCl 15–29 mL/min	Yes. Reduce dose in CrCl 15–29 mL/min	No
Interactions	Cyp 3A4 and P-gp	Cyp 3A4 and P-gp	P-gp